Despite its popularity, the Traditional Chinese Medicine (TCM) Market faces a significant "validation gap." Western regulators often demand placebo-controlled, Phase III clinical trials—a process that is prohibitively expensive for many traditional manufacturers. This hurdle can restrain the market by up to 1.1% of its potential CAGR in high-import regions like North America and the EU, where evidence-based guidelines determine hospital formulary inclusion.

Supply chain volatility is another critical challenge in 2025. Climate change has impacted the yields of essential medicinal plants, leading to price spikes for rare actives. For instance, the price of high-quality natural ingredients has surged, sometimes exceeding reimbursement ceilings. To combat this, the industry is shifting toward "Green Supply Chain Management" and blockchain tracking to ensure the authenticity and safety of herbs, specifically targeting the elimination of heavy-metal contamination and pesticide residues.

People Also Ask:

• What are the main regulatory challenges for TCM in Western countries?

• How does climate change impact the price of traditional herbs in 2025?

• What is being done to ensure the safety and purity of TCM products?